Company profile
Home - SolasCure
Our proprietary technology leverages biomimicry and evidence-based medicine to treat patients with chronic wounds.
Financial period: 1 Jul 2024 to 30 Jun 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0MTI0MDAwN2FkaXF6a2N4
Published 29 Oct 2024 10:39
CS01 | Transaction MzQzNzIyMzg4NWFkaXF6a2N4
Published 25 Sep 2024 03:56
Company registered at Companies House
1 Jun 2024 to 30 Apr 2026
Chronic wounds -- wounds that fail to heal in an appropriate time -- are a huge medical challenge, with the NHS spending over £6bn each year on their treatment. These wounds also have a major impact on patients' quality-of-life, causing both physical and psychological suffering. Worryingly, the number of people with chronic wounds is increasing rapidly, d...
1 Jan 2024 to 31 Dec 2027
Access to and delivery of affordable wound care are significant challenges to chronic wound patients. Globally, over 40 million people suffer from chronic wounds, and the economic burden of chronic wound treatment exceeds €100 billion annually. 1-2% of the populations of developed countries will experience a chronic wound in their lifetime. Chronic wounds...
